- Home
- RERE vs SGP Comparison
RERE vs SGP Comparison
Compare RERE & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RERE | SGP |
|---|---|---|
| Founded | 2011 | 2019 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 996.7M | 932.9M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | RERE | SGP |
|---|---|---|
| Price | $4.68 | $21.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $45.00 |
| AVG Volume (30 Days) | ★ 970.3K | 51.9K |
| Earning Date | 05-19-2026 | 05-15-2026 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.70 | N/A |
| Revenue Next Year | $22.93 | N/A |
| P/E Ratio | $34.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.41 | $20.15 |
| 52 Week High | $6.47 | $30.56 |
Technical Indicators
Market Signals| Indicator | RERE | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 49.16 | 36.44 |
| Support Level | $4.27 | N/A |
| Resistance Level | $4.87 | $26.29 |
| Average True Range (ATR) | 0.27 | 1.54 |
| MACD | 0.05 | -0.28 |
| Stochastic Oscillator | 41.67 | 2.59 |
Price Performance
Historical ComparisonAbout RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platforms PJT Marketplace and Paipai Marketplace. The Company's principal operations and geographic markets are in the People's Republic of China.
About SGP SpyGlass Pharma Inc. Common Stock
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.